Article
Stronger together: Analytical techniques for recombinant adeno associated virus
25 Nov 2021
Abstract excerpt
With recent FDA approval of two recombinant adeno-associated virus (rAAV)-based gene therapies, these vectors have proven that they are suitable to address monogenic diseases. However, rAAVs are relatively new modalities, and their production and therapy costs significantly exceed those of conventional biologics. Thus, significant efforts are made to improve the processes, methods, and techniques used in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
